After 4 years leading comms & IR at @inozyme, from preclinical science to Phase 3, I’m proud to share we’ve entered a definitive agreement to be acquired by @BioMarin.
A huge milestone for the program, the team, and the ENPP1 Deficiency community. $INZY $BMRN
Anecdotal indicator that biotech may be picking back up: In 2H22, there was a sharp drop-off in emails from recruiters trying to hire biotech IR people. Now we're back to multiple emails/day -- mostly companies that are already public, but a few pre-IPO as well.
I am proud to share these positive data which indicate that we can meaningfully improve the lives of those living with rare mineralization disorders.
Particularly fitting ahead of #RareDiseaseDay later this month.